Hansen's Disease
Leprosy is usually taught as a list of types with unfamiliar names and a treatment table. Held that way it is almost impossible to remember.
One idea makes it coherent: leprosy is a disease of the host immune response, not of the bacillus.
Mycobacterium leprae is the same organism in every patient. What differs is how vigorously cell-mediated immunity attacks it, and that single variable determines everything: how many bacilli are present, how many lesions appear, whether they are symmetrical, how nerves are damaged, and which kind of reaction the patient will have.
A second idea completes the picture. Nerve damage, not infection, is what disables, and most nerve damage happens during reactions, which can occur before treatment, during it, and for years afterwards.
Together these explain the clinical paradox that defines the disease: a patient can be bacteriologically cured and still lose a hand.
1. The Organism and Why It Chooses Cool Places
M. leprae is an obligate intracellular acid-fast bacillus that has never been cultured on artificial media, which is why diagnosis rests on clinical criteria and smears rather than culture.
Two properties explain the clinical picture.
It grows best at around 27 to 30 degrees Celsius, well below core temperature. This is why disease concentrates in the cooler parts of the body: skin, superficial peripheral nerves, the nasal mucosa, the anterior eye, the earlobes and the testes, while deep organs are spared.
Its doubling time is roughly 12 to 14 days, extraordinarily slow for a bacterium. Incubation therefore runs from about two to five years in tuberculoid disease to twenty years or more in lepromatous disease, and treatment is measured in months rather than days.
Transmission is chiefly by nasal droplets from untreated multibacillary patients, and susceptibility is genetically influenced, which is why prolonged household contact matters more than casual exposure.
2. The Ridley-Jopling Spectrum
The spectrum is a single axis: cell-mediated immunity, from strong to absent. Everything else follows from position on it.
| Feature | TT | BT | BB | BL | LL |
|---|---|---|---|---|---|
| Cell-mediated immunity | Strong | Good | Unstable | Poor | Absent |
| Bacilli | Absent | Scanty | Moderate | Many | Very many |
| Lesions | Single or few | Few | Intermediate | Many | Numerous |
| Symmetry | Asymmetric | Asymmetric | Variable | Tending symmetric | Symmetric |
| Nerve damage | Early, severe, few nerves | Early | Variable | Later, many nerves | Late, widespread |
| Lepromin test | Positive | Positive | Negative | Negative | Negative |
Two counterintuitive points fall out of the table.
Tuberculoid disease has almost no bacilli yet causes severe nerve damage, because the vigorous granulomatous response destroys the nerve it is defending. The immune response is the injury.
Lepromatous disease teems with bacilli yet damages nerves late, because there is little inflammatory response at all. Damage there is by sheer bacterial load and is widespread but slow.
The borderline groups are immunologically unstable, which is exactly why they are the ones that react.
The lepromin test is not a diagnostic test. It measures cell-mediated immunity, so it classifies and prognosticates: positive at the tuberculoid pole, negative at the lepromatous pole.
Indeterminate leprosy is the earliest form, a single hypopigmented macule with vague sensory change, which either heals spontaneously or evolves toward one pole.
3. Why Nerves
M. leprae invades Schwann cells, and this is the fact from which all disability follows.
Nerve involvement produces three deficits: sensory loss, motor weakness and autonomic loss. The autonomic loss is often forgotten and matters greatly, because loss of sweating leaves skin dry and fissured, which is how ulcers begin.
Peripheral nerves are affected where they are superficial and cool, which explains a list that otherwise looks arbitrary.
| Nerve | Deficit |
|---|---|
| Ulnar, commonest | Claw hand of ring and little fingers, sensory loss on the medial hand |
| Median | Ape thumb deformity, loss of thumb opposition |
| Common peroneal | Foot drop |
| Posterior tibial | Anaesthetic sole, plantar trophic ulcers, clawing of toes |
| Facial | Lagophthalmos, with exposure keratitis |
| Great auricular | Palpably thickened, visible in the neck |
Thickened peripheral nerves are close to specific for leprosy in the appropriate setting, and palpating nerves is part of the examination rather than an optional extra.
The posterior tibial nerve deserves emphasis, because an anaesthetic sole is what produces the plantar ulcer, the secondary infection, the osteomyelitis and eventually the shortened, deformed foot. The patient does not lose the foot to bacilli; they lose it to walking on a limb they cannot feel.
Two Indian variants worth knowing
Pure neuritic leprosy presents with nerve thickening and a neurological deficit and no skin lesion at all. It is reported far more often from India than from most other settings, and it is missed precisely because clinicians look for a patch. Nerve palpation and sensory mapping make the diagnosis.
Histoid leprosy is a lepromatous variant with discrete shiny nodules on apparently normal skin, an extremely high bacillary load, and characteristic spindle-shaped histiocytes on histology. It classically arises in patients with irregular treatment or dapsone resistance.
4. Making the Diagnosis
The World Health Organization defines three cardinal signs, and any one of them establishes the diagnosis.
A definite loss of sensation in a pale or reddish skin patch. A thickened or enlarged peripheral nerve, with loss of sensation or weakness in the muscles it supplies. The presence of acid-fast bacilli in a slit-skin smear.
Slit-skin smears are taken from cool sites, typically earlobes and active lesion edges, and are reported as a bacteriological index on a logarithmic scale.
The clinical test that matters most is simple and is often done badly. Sensory testing of a patch must be done with the patient's eyes closed, comparing the lesion with adjacent normal skin, testing light touch first, since it is lost before pain and temperature in most patches.
The important negative is that a hypopigmented patch without sensory loss is far more likely to be pityriasis alba, tinea versicolor, post-inflammatory hypopigmentation or vitiligo. Sensory loss is what makes the patch suspicious.
5. Treatment
For treatment purposes, patients are classified operationally rather than by Ridley-Jopling.
Paucibacillary disease means one to five skin lesions with a negative slit-skin smear. Multibacillary disease means more than five lesions, or any positive smear, or nerve involvement of more than one nerve trunk.
The World Health Organization moved to a uniform three-drug regimen of rifampicin, clofazimine and dapsone for both categories, differing only in duration: six months for paucibacillary disease and twelve months for multibacillary disease. India revised its classification and treatment protocols in line with this, with the change taking effect from April 2025.
Rifampicin is the key bactericidal agent, and a single dose kills the great majority of viable organisms, which is why patients become non-infectious quickly.
Single-dose rifampicin as post-exposure prophylaxis is offered to contacts of newly diagnosed patients and is one of the few interventions targeting transmission rather than disease.
Two counselling points prevent avoidable harm. Clofazimine causes reversible reddish-brown skin discolouration, which is a leading cause of default and should be explained before it appears. And dapsone can cause haemolysis, particularly in glucose-6-phosphate dehydrogenase deficiency, as well as methaemoglobinaemia and the rare dapsone hypersensitivity syndrome.
6. Reactions: Where the Damage Happens
Reactions are acute inflammatory episodes on a chronic disease, and they are the emergencies of leprosy. They can occur before diagnosis, during treatment, or years after cure.
| Feature | Type 1, reversal | Type 2, erythema nodosum leprosum |
|---|---|---|
| Mechanism | Type IV delayed hypersensitivity | Type III immune complex deposition |
| Patients | Borderline: BT, BB, BL | Lepromatous and BL, high bacterial load |
| Skin | Existing lesions become red, swollen, tender | Crops of new tender subcutaneous nodules |
| Systemic | Usually mild | Fever, malaise, arthralgia, iritis, orchitis, neuritis |
| Nerve | Acute neuritis, rapid loss of function | Neuritis common |
| Treatment | Systemic corticosteroids, tapered slowly | Steroids, thalidomide, clofazimine |
The single most important management rule is that antileprosy treatment is never stopped during a reaction. A reaction is an immunological event, not a treatment failure, and stopping the drugs allows bacterial multiplication to resume while doing nothing for the inflammation.
Type 1 reactions
These are the commonest cause of sudden nerve function loss. Corticosteroids are the treatment and the timing is what determines outcome.
Nerve function impairment treated within about six months of onset has a substantially better chance of recovery, which makes a new weakness or new sensory loss an urgent presentation rather than a routine one.
Type 2 reactions
Erythema nodosum leprosum is immune complex mediated and systemic, with tumour necrosis factor alpha central to its pathogenesis.
Thalidomide is the most effective drug for severe ENL, acting by inhibiting tumour necrosis factor alpha, and comparative work in Indian centres has found thalidomide with steroid more effective than clofazimine with steroid, with roughly 80 per cent non-recurrence against 66 per cent. Low-dose regimens appear as effective as high-dose ones.
Its use is constrained absolutely by teratogenicity, so it requires strict pregnancy prevention and is avoided in women of childbearing potential where alternatives exist. Clofazimine at higher dose is valuable in chronic ENL but acts too slowly for the acute severe episode.
Lucio phenomenon is a distinct and severe reaction seen in diffuse lepromatous leprosy, with necrotic ulcerating lesions from vasculitis and endothelial invasion.
7. Disability and Its Prevention
Grade 2 disability, meaning visible deformity or damage, is the indicator by which programmes are now judged, because it reflects delay in diagnosis better than case numbers do.
Prevention is not complicated but is often neglected.
Self-care is the core intervention. Daily soaking and oiling of dry anaesthetic skin, daily inspection of hands and feet for injuries the patient cannot feel, protective footwear with a moulded insole, and immediate rest for any ulcer.
Eye care follows the same logic. Lagophthalmos leaves the cornea exposed and anaesthetic, so the patient neither blinks nor feels the damage, and lubrication with regular review prevents an avoidable blindness.
Physiotherapy preserves range of movement in a clawed hand, and reconstructive surgery has a role once disease is inactive.
8. The Indian Picture
India achieved elimination of leprosy as a public health problem, defined as prevalence below one per 10,000, at national level in December 2005.
That achievement is frequently misread. India still reports more than 100,000 new cases each year, roughly 60 per cent of the global total, and the annual new case detection rate has plateaued rather than fallen since elimination was declared.
A plateau in new case detection means transmission is continuing, whatever the prevalence figure says. The disease burden is also very unevenly distributed, with around 80 districts reporting more than 20 new cases per 100,000 and a smaller group exceeding 50.
The National Leprosy Eradication Programme now focuses on early detection, reducing grade 2 disability, contact tracing with single-dose rifampicin prophylaxis, and addressing stigma, which remains a major driver of late presentation.
9. Worked Examples
Example 1. A 26-year-old has a single well-defined hypopigmented patch on the arm with a raised margin, complete loss of sensation, and a palpably thickened ulnar nerve on the same side. Slit-skin smear is negative. Classify and treat.
Borderline tuberculoid or tuberculoid disease on the Ridley-Jopling spectrum, given a single asymmetric well-defined lesion with a negative smear, which indicates strong cell-mediated immunity. For treatment purposes this is paucibacillary disease, being one to five lesions with a negative smear. He receives the uniform three-drug regimen of rifampicin, clofazimine and dapsone for six months.
The thickened ulnar nerve is the finding that requires the closest follow-up, since tuberculoid disease damages nerves early and severely despite having almost no bacilli, because the granulomatous response itself destroys the nerve.
Example 2. A patient two months into multibacillary treatment develops fever, crops of tender red nodules over the limbs and trunk, painful eyes and testicular pain. What is happening and should treatment be stopped?
Type 2 reaction, erythema nodosum leprosum, an immune complex mediated systemic event occurring in patients with a high bacterial load. The systemic features of fever, iritis and orchitis distinguish it from a type 1 reaction, which is largely confined to existing skin lesions and nerves.
Antileprosy treatment must not be stopped. A reaction is an immunological event rather than treatment failure, and stopping the drugs allows bacterial multiplication to resume while doing nothing for the inflammation.
Severe ENL is treated with corticosteroids, with thalidomide being the most effective agent because tumour necrosis factor alpha is central to the pathogenesis, subject to absolute precautions against pregnancy.
Example 3. A patient who completed treatment two years ago presents with new weakness of foot dorsiflexion over ten days. He is told he is cured and reassured. Comment.
The reassurance is wrong and the delay is harmful. Reactions occur before, during and after completion of treatment, and a new motor deficit indicates acute neuritis, most likely a type 1 reversal reaction affecting the common peroneal nerve. Bacteriological cure does not prevent immunological events.
This is urgent because nerve function impairment treated within about six months of onset has a substantially better prospect of recovery than impairment treated later, and every week of delay reduces the chance of regaining dorsiflexion. He needs systemic corticosteroids with a slow taper, splinting to prevent contracture, and documented serial assessment of nerve function.
Example 4. Explain why a tuberculoid patient with almost no demonstrable bacilli suffers worse nerve damage than a lepromatous patient teeming with them.
Because in leprosy the immune response, not the bacillus, causes the tissue injury. In tuberculoid disease cell-mediated immunity is vigorous, and the granulomatous inflammation mounted against a handful of organisms within Schwann cells destroys the nerve in the process of containing them. The result is early, severe damage confined to a small number of nerves, with correspondingly few bacilli on smear.
In lepromatous disease cell-mediated immunity is absent, so bacilli multiply almost unopposed but provoke little inflammation. Nerve damage there is caused by sheer bacterial load, appears later, and is widespread but more gradual. This is also why the borderline groups, whose immunity is unstable, are the ones that react, and why reactions rather than infection cause most disability.
Example 5. A patient with a healed plantar ulcer returns with a new deep ulcer under the same metatarsal head. He has been taking his medication faithfully. What has gone wrong?
Nothing has gone wrong with the antibacterial treatment, which is the point. He has posterior tibial nerve damage giving an anaesthetic sole, so he continues to walk normally on a foot that cannot report injury, and repetitive pressure at the metatarsal head breaks the skin without pain to warn him. Autonomic loss compounds this, since absent sweating leaves the skin dry and fissured.
Antileprosy drugs do not restore sensation and therefore cannot prevent this cycle.
What prevents it is self-care: daily inspection of the feet for injuries he cannot feel, soaking and oiling of dry skin, protective footwear with a moulded insole to redistribute pressure, and immediate rest of any ulcer until healed. Without that, the sequence runs to secondary infection, osteomyelitis and a shortened deformed foot.
Summary
Leprosy is a disease of the immune response; position on the cell-mediated immunity spectrum decides everything else.
M. leprae cannot be cultured and grows best at 27 to 30 degrees, which is why cool sites are affected.
Doubling time is 12 to 14 days, so incubation runs from years to decades.
Tuberculoid disease has few bacilli but severe early nerve damage; lepromatous disease has many bacilli and late, widespread damage.
The lepromin test classifies rather than diagnoses, and is positive at the tuberculoid pole.
M. leprae invades Schwann cells, causing sensory, motor and autonomic loss.
The ulnar nerve is the commonest affected; thickened nerves are near-specific for leprosy.
Any one of the three cardinal signs establishes the diagnosis.
A hypopigmented patch without sensory loss is usually not leprosy.
Paucibacillary is one to five lesions with a negative smear; multibacillary is more than five or any positive smear.
The uniform three-drug regimen is rifampicin, clofazimine and dapsone, for 6 months or 12 months.
Single-dose rifampicin prophylaxis is offered to contacts.
Warn patients about clofazimine discolouration before it appears, since it drives default.
Type 1 reactions are type IV hypersensitivity in borderline disease, treated with steroids.
Type 2 reactions are immune complex mediated in lepromatous disease, with systemic features.
Thalidomide is most effective for severe ENL but is absolutely constrained by teratogenicity.
Never stop antileprosy treatment during a reaction.
Nerve function impairment treated within six months has much better recovery.
Disability comes from walking on an insensate foot, not from bacilli.
India reports over 100,000 new cases a year, about 60 per cent of the global total, with a plateaued detection rate indicating continuing transmission.
